Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVE-CD study of early versus late vedolizumab use in Crohn's disease
NL-OMON53012Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of vedolizumab in Crohn's disease and inflammatory bowel disease (IBD) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Clinical and endoscopic remission at Week 26 and Clinical and endoscopic remission at Week 52-54. Started Aug 2015; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON53012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53012.